Gero
Commercial
About
Gero is a privately held, preclinical-stage biotechnology company headquartered in Singapore, with a U.S. subsidiary in San Francisco, that applies physics-based modelling and AI to large longitudinal human health datasets to find drug targets for age-related diseases and aging itself. Its models, trained on curated longitudinal medical records integrated with molecular, omics and genetic data, aim to separate reversible disease processes from slower, irreversible aging processes. Its Fedichev-Gruber framework classifies interventions into hallmark-targeting drugs, noise-reducing drugs and entropy-controlling drugs, and the company says its platform targets the latter two. In 2025 it signed a joint research and license agreement with Chugai Pharmaceutical (Roche Group) for antibodies against Gero-identified targets and released ProtoBind-Diff, a generative model for small-molecule design from protein sequence. It previously had a 2023 research collaboration with Pfizer on fibrotic disease targets.
Rating breakdown
Aggregate 37/100 · rank #10 in the commercial table full ratings →
Expand a signal to see what contributes to it.
Publications95
- Brian Kennedy — h-index 100 source ↗
- Peter Fedichev — h-index 43 source ↗
- Jan Gruber — h-index 37 source ↗
- Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit (Nature Communications) ↗
- Unsupervised learning of aging principles from longitudinal data (Nature Communications) ↗
- Germline burden of rare damaging variants negatively affects human healthspan and lifespan (eLife) ↗
- A minimal model explains aging regimes and guides intervention strategies (Fedichev & Gruber, bioRxiv preprint; basis of the Fedichev-Gruber theory) ↗
- Extracting biological age from biomedical data via deep learning: too much of a good thing? (Pyrkov et al., Scientific Reports) ↗
Discovery32
Trials from ClinicalTrials.gov (this org as lead sponsor), matched to aging by their condition or intervention.
Development0
No clinical-stage geroprotective trials recorded.
Fundraising62
Education5
- Peter Fedichev ARDD speaker 2025 source ↗
Key outputs
- publication Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit (Nature Communications) ↗ 2021
- publication Unsupervised learning of aging principles from longitudinal data (Nature Communications) ↗ 2022
- publication Germline burden of rare damaging variants negatively affects human healthspan and lifespan (eLife) ↗ 2020
- publication A minimal model explains aging regimes and guides intervention strategies (Fedichev & Gruber, bioRxiv preprint; basis of the Fedichev-Gruber theory) ↗ 2025
- dataset or tool ProtoBind-Diff, structure-free diffusion language model for protein sequence-conditioned small-molecule (ligand) design; open-source code and weights on GitHub ↗ 2025
- publication Extracting biological age from biomedical data via deep learning: too much of a good thing? (Pyrkov et al., Scientific Reports) ↗ 2018
- publication Deep longitudinal phenotyping of wearable sensor data reveals independent markers of longevity, stress, and resilience (Pyrkov et al., Aging) ↗ 2021
- other Gero named a World Economic Forum 2026 Technology Pioneer for advancing the physics of aging in drug discovery ↗ 2026
Registered clinical trials
5 trials list this organisation as lead sponsor ClinicalTrials.gov ↗
- Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls ↗ PHASE2 · UNKNOWN · 2024-05-21
- High Protein Dairy Products and Resistance Exercise in the Elderly ↗ NA · COMPLETED · 2023-06-01
- The Right Heart During and After Pregnancy - an Echocardiographic Study ↗ UNKNOWN · 2017-11-02
- Defining Benchmarks in Bariatric Surgery ↗ COMPLETED · 2017-10-17
- Community-based Cohort of Functional Decline in Subjective Cognitive Complaint Elderly ↗ UNKNOWN · 2017-09-25
Financial
Financing rounds
| Date | Amount | Round | Investors |
|---|---|---|---|
| 2023-10 | USD 6M | Gero publicly disclosed a $6M financing (October 2023) | |
| 2026-06 | USD 17M | Gero publicly disclosed $17M in new equity financing (June 2026) | Melnichek Investments |
| 2026-06 | USD 34M | Gero publicly disclosed total equity funding of $34M (as of June 2026) |
Key people
Research fields
Links
Sources
- https://www.gero.ai/
- https://www.gero.ai/team
- https://www.gero.ai/news
- https://www.businesswire.com/news/home/20260617389034/en/Gero-Reaches-%2434M-in-Equity-Funding-to-Turn-the-Physics-of-Aging-Into-Medicines
- https://www.financialcontent.com/article/bizwire-2026-6-17-gero-reaches-34m-in-equity-funding-to-turn-the-physics-of-aging-into-medicines
- https://www.businesswire.com/news/home/20231018615272/en/Physics-Powered-GenAI-Biotech-Gero-Raises-%246M-to-Find-Root-Causes-of-Aging-and-Age-Related-Diseases
- https://www.chugai-pharm.co.jp/english/news/detail/20250707160000_1156.html
- https://www.globenewswire.com/news-release/2025/07/14/3114721/0/en/Gero-Appoints-Longevity-Expert-Dr-Brian-Kennedy-to-Board-of-Directors.html
- https://www.globenewswire.com/news-release/2025/06/25/3105040/0/en/gero-launches-protobind-diff-a-structure-free-ai-foundation-model-for-targeted-small-molecule-discovery.html
- https://www.pfizer.com/news/press-release/press-release-detail/longevity-biotech-gero-entered-research-collaboration
- https://doi.org/10.1038/s41467-021-23014-1
- https://doi.org/10.1038/s41467-022-34051-9
- https://doi.org/10.7554/eLife.53449
- https://doi.org/10.1101/2025.08.25.671954
- https://doi.org/10.1038/s41598-018-23534-9
- https://doi.org/10.18632/aging.202816
- https://doi.org/10.1101/2025.06.16.659955
- https://github.com/gero-science/ProtoBind-Diff
- https://www.businesswire.com/news/home/20260610353659/en/Gero-Named-World-Economic-Forum-2026-Technology-Pioneer-for-Advancing-the-Physics-of-Aging-in-Drug-Discovery